Skip to content

SONOlysis in Risk REduction of Symptomatic and Silent Brain infarCtions dUring Cardiac surgEry

Risk Reduction of Symptomatic and Silent Brain Infarctions During Cardiac Surgery Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01591018
Acronym
SONORESCUE
Enrollment
120
Registered
2012-05-03
Start date
2012-09-30
Completion date
2015-07-31
Last updated
2020-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Bypass Graft Redo, Heart Valve Diseases

Keywords

sonolysis, brain infarction, prevention, cardiac surgery

Brief summary

The aim of the project is to demonstrate a fibrinolytic effect of sonothrombolysis (continual transcranial Doppler monitoring) using 2 MHz diagnostic probe on the reduction of risk of brain infarctions due to the activation of endogenous fibrinolytic system during cardiac surgery (CS). 120 patients indicated for CS (CABG or valve replacement) will be enrolled into the study in order to demonstrate a twenty-percent risk reduction of number and volume of brain infarctions detected using MRI examination 24 hours after CEA or CS in 5% level of significance. Patients will be randomized - subgroup 1 will undergo a 40-240minute non-diagnostic TCD monitoring during CS, subgroup 2 will undergo interventions without TCD monitoring. The aim of the project is a concordance with the aim No 1 of the Resort Program of a Research and Development: Improvement of quality of life of patients using the modern therapeutic methods but with relative small positive effect of quality of life. The aim of the project is in concordance with a priority of announced public grant competition: Development of the new therapeutic methods of cardiovascular disorders, especially coronary heart disease and stroke. Confirmation of our hypothesis that sonothrombolysis is able to activate endogenous fibrinolytic system during CS with consecutive reduction of the number and volume of brain infarcts, can lead to the increase of the safety of CS in patients. We can presume that up to 50% of patients indicated for CS can be treated using these methods in the future.

Detailed description

AIM OF THE PROJECT The aim of the project is to demonstrate an effect of continual TCD monitoring using 2 MHz diagnostic probe with maximal diagnostic energy on the reduction of risk of brain microinfarctions due to the activation of endogenous fibrinolytic system and mechanical effect on emboli during CS. The aim of the project is a concordance with the aim No 1 of the Resort program of a research and development in the years 2010-2015: Improvement of quality of life of patients using the modern therapeutic methods but with relative small positive effect of quality of life. The aim of the project is in concordance with a priority of announced public grant competition: Development of the new therapeutic methods of cardiovascular disorders, especially coronary heart disease and stroke. HYPOTHESIS Sonothrombolysis lead to activation of fibrinolytic system in both healthy volunteers and acute stroke patients. In acute stroke patients, mechanical effect of sonothrombolysis is the second effect leading to acceleration of occluded artery recanalization. We hypothesize that combination of mechanical effect and activation of fibrinolytic system durin sonothrombolysis (TCD monitoring) during CS will lead to recanalization of small arterial occlusions caused by microembolization during intervention. The result will be reduction of volume and the number of brain infarctions in the territory of the monitored MCA. 120 patients indicated for CS will be enrolled into the study in order to demonstrate a twenty-percent risk reduction of number and volume of brain infarctions in the territory of athe monitored MCA detected using MRI examination 24 hours after CS in 5% level of statistical significance. Patients will be randomized into 2 subgroups. Subgroup 1 will undergo non-diagnostic TCD monitoring during CS. Subgroup 2 will undergo CS without TCD monitoring. PATIENTS AND METHODS Patients: 120 patients indicated for CS (isolated coronary artery bypass surgery or isolated heart valve surgery) will be enrolled into the study during a 3-year period. All 120 patients will be randomized for standard CS and TCD monitored CS. Clinical examinations: Physical and neurological examinations including evaluating of neurological impairment of neurological deficit in NIHSS scale, modified Rankin scale and cognitive testing (Mini Mental State Examination, Clock drawing test) will be performed before and 24 - 72 hours after CS. Randomization: Randomization using computer generated random allocation will be used, separately for coronary artery bypass surgery and valve surgery patients. Sonothrombolysis: In patients randomized into sonothrombolysis subgroup, MCA segment in depth 55 mm will be monitored for 40 - 240 minutes using a diagnostic 2 MHz probe with maximal diagnostic energy. Non-diagnostic TCD monitoring will be performed without detection of microembolic signals or detection of changes in blood flow. The second (control) subgroup will undergo a standard CS without sonothrombolysis. MRI protocol will consists of 4 sequences: 1. Localizer; 2. T2TSE; 3. FLAIR; 4. DWI. Sequences 1-3 will be applied in the same level, they will have the same slice thickness and the same cut number. The slice thickness comprises its own cut thickness (5 mm) + distant factor (30%). Standard number of slices is 19. Standard slice level is considered to be a modified level of skull base due to the minimalization of distant artifacts EPI sequence. T2TSE: TR=4000/TE=99/ETL=9, FOV 230, FOV ph. 75%, matrix 256x256. FLAIR: 8050/112/ETL=21/2 conc., FOV 230, FOV ph. 76,6%, matrix 256x151. EPI-DWI: 4200/139/EPI f.=96/6 av., FOV 230, FOV ph. 100%, phase enc. direction A-P, matrix 128x96 with interpolation, phase partial Fourier 6/8, Bw 1346 Hz/Px, echo spacing 0.83 ms, TA. Sequence called trace with three types of MR pictures in every slice: (a) T2\*EPI b=0; (b) DWI b=500; (c) DWI b=1000. The fourth type of images automatically created an ADC map (in-line postprocessing). DWI show a middle (average) diffusivity of every point of examined brain tissue when b value is 500 and 1000. This sequence is applied in order to assess hemorrhage (T2\*EPI) and monitor sites of reduced diffusion (DWI, b=500 and 1000). New infarctions will be evaluated only in the territory of treated ICA. Adverse effects: All adverse effects during 1 month after UM will be registered, especially all causes for new admissions to the hospital, worsening of neurological symptoms (\>4 points in NIH stroke scale), brain edema, symptomatic and asymptomatic intracranial bleeding detected in control brain MRI. Study protocol has been approved by the Ethics Committees in accordance with the principles and guidelines of the Declaration of Helsinki, 1975.

Interventions

PROCEDUREsonolysis

continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes

PROCEDUREcardiac surgery

coronary artery bypass graft (CABG) heart valve replacement

Sponsors

Palacky University
CollaboratorOTHER
Ministry of Health, Czech Republic
CollaboratorOTHER_GOV
University Hospital Ostrava
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* age 40-90 years, * sufficient temporal bone window for TCD with detectable blood flow in MCA, * independent patient (modified Rankin score 0-2), * informed consent signed by the patient, * CS will be performed as an elective surgery with an extracorporeal circulation

Exclusion criteria

* contra-indication for MRI examination (pace-maker, implanted metal material, claustrophobia), * emergent surgery, * acute myocardial infarction, * combined cardiac surgery, * combined cardiac and carotid surgery

Design outcomes

Primary

MeasureTime frameDescription
Number od Participants With New Brain Infarction in the Monitored MCA Territory Detected Using MRI24 hours after interventionto demonstrate a twenty-percent risk reduction of number and volume of brain infarctions and brain infarctions \> 0.5 cm3 in the monitored MCA territory in sonolysis group detected using MRI examination 24 hours after cardiac surgery in 5% level of statistical significance

Secondary

MeasureTime frameDescription
Cognitive Decline30 days after interventionTo demonstrate an effect of sonolysis on the reduction of cognitive decline after cardiac surgery measured by Adenbook´s Cognitive Examination - revised (ACE-R)ACE-R. Adenbook´s Cognitive Examination - revised (ACE-R) can aquire value 0 to 100. Higher value represents better cognitive functions.
Number of Participants With Clinical Manifested Brain Infarction30 days after interventionto demonstrate an effect of sonolysis on the reduction of risk of clinically stroke due to the activation of endogenous fibrinolytic system during cardiac surgery

Countries

Czechia

Participant flow

Participants by arm

ArmCount
Cardiac Surgery With Sonolysis
cardiac surgery (CABG or heart valve surgery) with sonolysis (continual transcranial Doppler monitoring) sonolysis: continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes cardiac surgery: coronary artery bypass graft (CABG) heart valve replacement
60
Cardiac Surgery Without Sonolysis
cardiac surgery (CABG or heart valve surgery) without sonolysis (continual transcranial Doppler monitoring) cardiac surgery: coronary artery bypass graft (CABG) heart valve replacement
60
Total120

Baseline characteristics

CharacteristicCardiac Surgery Without SonolysisTotalCardiac Surgery With Sonolysis
Age, Continuous69.0 years68 years66.5 years
Alcohol abuse
Abstinent or Social Drinker Participants
60 participants119 participants59 participants
Alcohol abuse
Alcohol Abuse Participants
0 participants1 participants1 participants
Arterial Hypertension
Participants with Arterial Hypertension
47 participants95 participants48 participants
Arterial Hypertension
Participants without Arterial Hypertension
13 participants25 participants12 participants
Atrial Fibrillation
Participants with Atrial Fibrillation
30 participants63 participants33 participants
Atrial Fibrillation
Participants without Atrial Fibrillation
30 participants57 participants27 participants
Coronary Heart Disease
Participants with Coronary Heart Disease
40 participants82 participants42 participants
Coronary Heart Disease
Participants without Coronary Heart Disease
20 participants38 participants18 participants
Diabetes Mellitus
Participants with Arterial Hypertension
19 participants42 participants23 participants
Diabetes Mellitus
Participants without Arterial Hypertension
41 participants78 participants37 participants
Hyperlipidemia
Participants with Hyperlipidemia
38 participants71 participants33 participants
Hyperlipidemia
Participants without Hyperlipidemia
22 participants49 participants27 participants
Internal carotid artery (ICA) stenosis ≥ 50%
Participants with ICA Stenosis
4 participants10 participants6 participants
Internal carotid artery (ICA) stenosis ≥ 50%
Participants without ICA Stenosis
56 participants110 participants54 participants
Myocardial Infarction in History
Participants with Myocardial Infarction
12 participants26 participants14 participants
Myocardial Infarction in History
Participants without Myocardial Inf.arction
48 participants94 participants46 participants
Sex: Female, Male
Female
28 Participants51 Participants23 Participants
Sex: Female, Male
Male
32 Participants69 Participants37 Participants
Smoking
Non-smokers
54 participants108 participants54 participants
Smoking
Smokers
6 participants12 participants6 participants
Transient Ischemic Attack (TIA) or Stroke
Participants without TIA or Stroke
57 participants114 participants57 participants
Transient Ischemic Attack (TIA) or Stroke
Participants with TIA or Stroke
3 participants6 participants3 participants
Type of surgery
Coronary Artery Bypass Graft
29 participants60 participants31 participants
Type of surgery
Valve Surgery
31 participants60 participants29 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 600 / 60
serious
Total, serious adverse events
42 / 6044 / 60

Outcome results

Primary

Number od Participants With New Brain Infarction in the Monitored MCA Territory Detected Using MRI

to demonstrate a twenty-percent risk reduction of number and volume of brain infarctions and brain infarctions \> 0.5 cm3 in the monitored MCA territory in sonolysis group detected using MRI examination 24 hours after cardiac surgery in 5% level of statistical significance

Time frame: 24 hours after intervention

ArmMeasureGroupValue (NUMBER)
Cardiac Surgery With SonolysisNumber od Participants With New Brain Infarction in the Monitored MCA Territory Detected Using MRIParticipants with new infraction8 participants
Cardiac Surgery With SonolysisNumber od Participants With New Brain Infarction in the Monitored MCA Territory Detected Using MRIParticipants without new infraction52 participants
Cardiac Surgery Without SonolysisNumber od Participants With New Brain Infarction in the Monitored MCA Territory Detected Using MRIParticipants with new infraction16 participants
Cardiac Surgery Without SonolysisNumber od Participants With New Brain Infarction in the Monitored MCA Territory Detected Using MRIParticipants without new infraction44 participants
Comparison: Sample size was based on an expected 20% reduction of new ischemic lesions on DW-MRI in the sonolysis group (estimated prevalence, 10%) compared with the control group (estimated prevalence, 30%).p-value: <0.05Chi-squared, Corrected
Secondary

Cognitive Decline

To demonstrate an effect of sonolysis on the reduction of cognitive decline after cardiac surgery measured by Adenbook´s Cognitive Examination - revised (ACE-R)ACE-R. Adenbook´s Cognitive Examination - revised (ACE-R) can aquire value 0 to 100. Higher value represents better cognitive functions.

Time frame: 30 days after intervention

Population: 50 out of 60 participants completed all cognitive tests in cardiac surgery with sonolysis group.~50 out of 60 participants completed all cognitive tests in cardiac surgery without sonolysis group.

ArmMeasureValue (MEDIAN)
Cardiac Surgery With SonolysisCognitive Decline80 units on a scale
Cardiac Surgery Without SonolysisCognitive Decline82 units on a scale
Secondary

Number of Participants With Clinical Manifested Brain Infarction

to demonstrate an effect of sonolysis on the reduction of risk of clinically stroke due to the activation of endogenous fibrinolytic system during cardiac surgery

Time frame: 30 days after intervention

Population: All enrolled participants were analyzed

ArmMeasureGroupValue (NUMBER)
Cardiac Surgery With SonolysisNumber of Participants With Clinical Manifested Brain InfarctionParticipants with clinical manifested infarction0 participants
Cardiac Surgery With SonolysisNumber of Participants With Clinical Manifested Brain InfarctionParticipants without clinical manifest. infarction60 participants
Cardiac Surgery Without SonolysisNumber of Participants With Clinical Manifested Brain InfarctionParticipants with clinical manifested infarction2 participants
Cardiac Surgery Without SonolysisNumber of Participants With Clinical Manifested Brain InfarctionParticipants without clinical manifest. infarction58 participants

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026